{"filing":{"accession_number":"0001493152-26-032938","cik":"0001582554","ticker":"MTNB","company_name":"Matinas BioPharma Holdings, Inc.","form":"8-K","filing_date":"2026-07-13","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315226032938/form8-k.htm"},"events":[{"id":17502,"run_id":15676,"accession_number":"0001493152-26-032938","anchor_item_number":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"The filing discloses entry into a definitive Business Combination Agreement on July 10, 2026, whereby Matinas BioPharma will merge with GH Power Inc. through a plan of arrangement, with GHP International becoming the public parent company. This is a material acquisition/change of control transaction expected to close in Q4 2026. The filing also discloses a concurrent definitive stock purchase agreement to divest Matinas BioPharma Nanotechnologies, Inc. (including MAT2203 and LNC platform) to Azurity Pharmaceuticals for $4.0 million upfront plus up to $17.5 million in milestones and royalties. Both transactions are disclosed under Item 1.01 (Entry into a Material Definitive Agreement) and constitute material M\u0026A activity.","company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","filing_date":"2026-07-13","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":16002,"accession_number":"0001493152-26-032938","item_number":null,"item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses entry into a definitive Business Combination Agreement on July 10, 2026, whereby Matinas BioPharma will merge with GH Power Inc. through a plan of arrangement, with GHP International becoming the public parent company. This is a material acquisition/change of control transaction expected to close in Q4 2026. The filing also discloses a concurrent definitive stock purchase agreement to divest Matinas BioPharma Nanotechnologies, Inc. (including MAT2203 and LNC platform) to Azurity Pharmaceuticals for $4.0 million upfront plus up to $17.5 million in milestones and royalties. Both transactions are disclosed under Item 1.01 (Entry into a Material Definitive Agreement) and constitute material M\u0026A activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T12:06:52.969516+00:00","company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","filing_date":"2026-07-13"}]}